Lobe Sciences 与 ArcStone Securities 合作，以提高投资者知名度，并为罕见病治疗筹集了 341,425 加元。 Lobe Sciences partners with ArcStone Securities to boost investor visibility and raises CAD 341,425 for rare disease treatments.

Lobe Sciences是一家以罕见疾病为重点的生物制药公司,它与ArcStone证券公司合作,加强其资本市场战略,并扩大其在投资者中的可见度。 Lobe Sciences, a biopharmaceutical company focused on rare diseases, has partnered with ArcStone Securities to enhance its capital markets strategy and expand its visibility among investors. 这种协作包括整个北美洲资本市场规划和战略定位,以通过创新推动价值。 This collaboration includes capital markets planning and strategic positioning across North America to drive value through innovation. 此外,Lobe Sciences还启动了私人投资,为一般公司目的筹集了341,425加元,包括推进状细胞疾病和慢性群头痛的治疗方法. Additionally, Lobe Sciences launched a private placement to raise up to CAD 341,425 for general corporate purposes, including advancing treatments for Sickle Cell Disease and Chronic Cluster Headache.